Please register or login to view the chart

QT Interval

QT interval is measured from the beginning of the QRS complex 
to the end of the T wave on the ECG and represents the period from 
the onset of depolarisation to the completion of repolarisation of the ventricular myocardium

QTc interval of 450 ms ( men ) and 460 ms
( women ) are generally 
accepted as upper limits of normal

Recognized risk factor for the occurrence of cardiac arrhythmias
○ VT /TdP
○ syncope
○ sudden death Particularly torsades de pointes ( TdP )
○ polymorphic ventricular tachyarrhythmia
○ on ECG → continuous twisting of the vector of the QRS complex around isolelectric baseline
○ Marked feature of TdP is pronounced prolongation of the QT interval in the supraventricular beat preceding the arrhythmia
○ TdP can degenerate into ventricular fibrillation leading to sudden death Qt interval varies greatly and is affected by age , sex , sympathetic tone and diurnal pattern The magnitude of the ↑↑ in QT interval from baseline is also helpful in evaluating the risk.

QT interval is from the beginning of the QRS complex to the end of the T wave- so it represents the complete ventricular depolarisation and repolarisation phase QT prolongation usually happens when there is a delay between the onset of depolarization and the completion of repolarization -which increases the action potential duration.

A reduction of net repolarizing ion channel currents resulting in a prolonged repolarisation

QTc ( QT corrected ) QT interval is inversely proportional to heart rate ie
QT interval increases as HR falls QTc is the interval corrected for HR @ 60 Several formulas exist to correct the QT interval Drug induced TdP is more commonly seen with bradycardias

Do not use QT prolonging drugs in patients with known LQTS-Consider the risk of QT prolongation when starting a new medication-Assess for risk factors for
 QT prolongation and overall
 risk of drug 
induced QT prolongation-If patient at ↑↑ risk of QT prolongation or already taking a drug that can ↑↑ QT consider an alternative drug which does not affect QT-Not practical to consider an 
ECG every time a QT
 prolonging medication is prescribed-When risk of QT prolongation
 is high consider baseline ECG before starting the medication and when the new drug 
reaches steady state 
( five half lives )-QTC of 470 – 500 ms in men
 QTc of 480- 500 ms in women
 An increase in QTc >= 60 ms


 QTC > 500 ms

What happens QT interval is from the beginning of the QRS complex to the end of the T wave- so it represents the complete ventricular depolarisation and repolarisation phase QT prolongation usually happens when there is a delay between the onset of depolarization and the completion of repolarization -which increases the action potential duration.
A reduction of net repolarising ion channel currents resulting in a prolonged repolarisation
This can trigger oscillations of the membrane potential which can give rise to additional depolarisations during repolarisation phase – called as early afterdepolarisations 
( EADs )
When the amplitude of EADs reaches a critical threshold and involves a sufficiently large myocardial area -ectopic ventricular beats can ensue with TdP being the most common arrhythmia

Brilliant website for all QT related issues https://crediblemeds.org
registration needed for list- free when checked last.

Steps to assess the risk- Assess the medication risk –Consider using the website CredibleMeds The website can access online or use a web app. CredibleMeds classifies medications based on QT prolonging potential in 4 types.

There are numerous 
manual and automated approaches to measure the QT interval- most accurate way to measure is to use high 
resolution digital 12 lead 
ECG extracted from 
continuous 12-lead Holter monitoring

Review dose , route of administration and interactions –Risk is dose dependent – risk increases as a function of dose and plasma drug interactions Pharmacokinetic interactions can be checked via 
https://reference.medscape.com/drug-interactionchecker

Decide if an ECG is needed –Ensure that the automatic ECG machine-has correct patient data input as age and sex Consider an ECG if 
○ there is a h/o CVD or family h/o CVD
○ patient on high dose of anti-psychotic medications
○ patient has risk factors which may predispose to arrhythmia Indications for obtaining a baseline ECG and or routine / ECG monitoring prior to treatment with a QT prolonging medication is mixed in literature It is not practical to obtain an ECG each time a QT prolonging medication is prescribed

Can we minimize the risk –Optimise any identifiable & modifiable risk factor ( or factors ) Do not use a QT prolongation drug if known LQTS Assume that all anti-psychotics carry and increased risk of sudden cardiac death Consider using lowest dose possible of a QT prolonging drug is no other alternative is available

Assess the patients risk of QTc prolongation and TdP Consider the modifiable and non-modifiable risk factors Patients with underlying heart problems for e.g Long QT syndrome , myocardial infarction , cardiomyopathy , cardiac arrhythmia , bradycardia or CCF are more prone to affects of QT prolongation Tools as those developed by Tisdale can be used to assess individual risk

Cardiology advice –If seeking cardiology advice – collect the following data
 full list of prescribed medications has the patient reported faintness , near collapse or collapse episodes known cardiac history / conditions what was the patient’s heart rate and QTc before therapy prior to using a QT prolonging medication latest HR and QTc biochemical profile within last 2 weeks

References

 Drug Induced QT Interval Prolongation National Medicine Information Center Volume 21 Number 6 2015 Drug Induced QT Prolongation PostScriptExtra Issue 21 , December 2012 NHS Glasgow and Clyde Medicines Information Service The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic European Medicines Agency November 2005 CHMP/ICH/2/04 Drug-induced QT interval prolongation : mechanisms and clinical management Ther Adv Drug Saf . 2012 Oct ; 3(5) : 241-253 Drug-Induced QTc Interval Prolongation : A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice Current Drug safety , 2016 , 11 , 86-98 QT Interval and drug therapy drug and Therapeutics Bulletin BMJ 2016 ; 353 :i2732 QT Interval Edward Burns from https://lifeinthefastlane.com/ecg-library/basics/qt_interval/ My Approach to the patient with a borderline long QT Interval Trends in Cardiovascular Medicine Roston Thomas MD October 1 , 2017 , Issue 7 . Pages 516-517 Long QT syndrome BMJ Best Practice Sudden Arrhythmia Death Syndrome : Importance of the Long QT Syndrome AAFP Drug and non drug – associated QT interval prolongation Br J Clin Pharmacol . 2010 Jul ; 70 ( 1) : 16-23 Website snapshot from https://crediblemeds.org


INFORMATION FOR CLINICIANS

Calculator -from MD Calc https://www.mdcalc.com/corrected-qt-interval-qtc

Credible Meds a wonderful resource https://www.crediblemeds.org/

A 35 page PP presentation by Dr Adrian Stanleyhttps://www.ukmi.nhs.uk/filestore/ukmiamt/ProlongedQTDrugsSept2015.pdf

References

  1. Lambiase, Pier D et al. “British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication.” Arrhythmia & electrophysiology review vol. 8,3 (2019): 161-165. doi:10.15420/aer.2019.8.3.G1 
  2. Guidelines for the Management of QTc Prolongation in Adults Prescribed Antipsychotics NHS Tees , Esk and Wear Valleys NHS Foundation Trust https://www.england.nhs.uk/north/wp-content/uploads/sites/5/2018/12/QTc-flow-diagram-with-medications-final-Dec-17-A3-with-logos.pdf
  3. Giselle Sarganas, Edeltraut Garbe, Andreas Klimpel, Rolf C. Hering, Elisabeth Bronder, Wilhelm Haverkamp, Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany, EP Europace, Volume 16, Issue 1, January 2014, Pages 101–108, https://doi.org/10.1093/europace/eut214
  4. Schwartz, Peter J et al. “Prevalence of the congenital long-QT syndrome.” Circulation vol. 120,18 (2009): 1761-7. doi:10.1161/CIRCULATIONAHA.109.863209 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784143/
  5. Isbister, G.K. and Page, C.B. (2013), Clinical assessment of drug‐induced QT prolongation. Br J Clin Pharmacol, 76: 48-57. doi:10.1111/bcp.12040
  6. Management of prolonged Qt interval and torsades de pointes in the intoxicated patient
    A.A. Kan1*, D.W. de Lange1,2,3, D.W. Donker2, J. Meulenbelt  Netherlands The Journal of Medicine April 2014 , Vol 72 , No 3 , 119 http://www.njmonline.nl/getpdf.php?id=1423
  7. Zolezzi, M, and L Cheung. “A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population.” Neuropsychiatric disease and treatment vol. 15 105-114. 24 Dec. 2018, doi:10.2147/NDT.S186474
  8. ECG Basics from Healio com QT Interval https://www.healio.com/cardiology/learn-the-heart/ecg-review/ecg-interpretation-tutorial/qt-interval
  9. Gomez, Andrew T et al. “Evaluation and Management of Athletes With Long QT Syndrome.” Sports health vol. 8,6 (2016): 527-535. doi:10.1177/1941738116660294
  10. Drug Induced QT Interval Prolongation National Medicine Information Center Volume 21 Number 6 2015
  11. Drug Induced QT Prolongation Post ScriptExtra Issue 21 , December 2012
  12. NHS Glasgow and Clyde Medicines Information Service  The Clinical Evaluation of QT/QTc
  13. Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic European Medicines Agency November 2005 CHMP/ICH/2/04
  14. Drug-induced QT interval prolongation : mechanisms and clinical management Ther Adv Drug Saf . 2012 Oct ; 3(5) : 241-253
  15. Drug-Induced QTc Interval Prolongation : A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice Current Drug safety , 2016 , 11 , 86-98
  16. QT Interval and drug therapy drug and Therapeutics Bulletin BMJ 2016 ; 353 :i2732
  17. QT Interval Edward Burns from https://lifeinthefastlane.com/ecg-library/basics/qt_interval/
  18. My Approach to the patient with a borderline long QT Interval Trends in Cardiovascular Medicine Roston Thomas MD October 1 , 2017 , Issue 7 . Pages 516-517
  19. Long QT syndrome BMJ Best Practice Sudden Arrhythmia Death Syndrome
  20. Importance of the Long QT Syndrome AAFP Drug and non drug – associated
  21. QT interval prolongation Br J Clin Pharmacol . 2010 Jul ; 70 ( 1) : 16-23 
  22. McClelland, Justine, and Monica Mathys. “Evaluation of QTc prolongation and dosage effect with citalopram.” The mental health clinician vol. 6,4 165-170. 29 Jun. 2016, doi:10.9740/mhc.2016.07.165

Share

Related Charts:

Add Your Comments

Your email address will not be published. Required fields are marked *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

A4 Medicine  - Search Less and Learn More

Welcome to the A4 medicine community where we are constantly working to provide exceptional educational material to primary health care professionals. Subscribe to our website for complete access to our A4 Charts. They are aesthetically designed charts that contain 300 (plus and adding) common and complex medical conditions with the all information required for primary care in one single page that can help you in consultation/practice and exam.

Additionally, you will get complete access for our Learn From Experts : A4 Webinar Series in which domain experts share the video explainer presentation on one medical condition in one hour for the primary care. And you will also get a hefty discount on our publications and upcoming digital products.

We are giving a lifetime flat 30% discount to our first thousand users, discount code already applied to checkout.